anemia%20-%20iron-deficiency
ANEMIA - IRON-DEFICIENCY
Anemia is a condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) and/or hematocrit (intact RBC in blood) making it insufficient to address the physiologic needs of the body.
Iron-deficiency anemia is the anemia that resulted from inadequate iron supplementation or excessive blood loss.
It is the most common nutritional disorder worldwide and accounts for more than half of anemia cases.
It is prevalent among preschool children and pregnant women.

Drug Information
Iberet Folic-500
ascorbic acid + calcium pantothenate + cyanocobala...

Indication: Prevention & treatment of Fe-deficiency anemia & prevention of folate deficiency.

Indication: Fe deficiency where there is a clinical need for rapid Fe correction or when oral Fe is ineffective or cannot ...

Indication: Dietary supplement for the prevention of neural tube defect.

Appeton Essentials Natal Care
betacarotene + calcium + calcium lactate + copper ...

Indication: Vit & mineral supplement for pregnant & lactating women.

Indication: Fe deficiency when clinically needed to deliver Fe rapidly to Fe stores, in patients who cannot tolerate or ar...

Indication: Fe deficiency in adults when oral Fe prep cannot be used due to intolerance or in case of demonstrated lack of...

Ferrocyte
sodium ferrous citrate

Indication: Fe-deficiency anemia.

Indication: Fe deficiency anaemia where there is clinical need for rapid Fe supply, in patients who cannot tolerate or are...

Indication: Fe deficiency w/ & w/o anaemia. Prophylaxis of Fe deficiency during pregnancy.

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.